Trial Profile
Effects of peroral levosimendan in the prevention of further hospitalisations in patients with chronic heart failure. A randomised, phase II double-blind, placebo-controlled, multi-centre, parallel-group study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2011
Price :
$35
*
At a glance
- Drugs Levosimendan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- 05 Nov 2005 New trial record.